Poseltinib

Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis.^[1] It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly.^[2]

Poseltinib

Clinical data
Other names	HM-7122; LY 3337641
Identifiers
IUPAC name N-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
CAS Number	1353552-97-2
PubChem CID	56644522
UNII	D01E4B1U35
CompTox Dashboard (EPA)	DTXSID501112972
Chemical and physical data
Formula	C26H26N6O3
Molar mass	470.533 g·mol−1
3D model (JSmol)	Interactive image
SMILES C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1
InChI InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30) Key:LZMJNVRJMFMYQS-UHFFFAOYSA-N

Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.^[3]